摘要
目的探讨参麦注射液联合TC化疗方案对中晚期卵巢癌的临床疗效、免疫功能以及毒性作用。方法选取陕西中医药大学第二附属医院2017年1月-2018年1月收治的中晚期卵巢癌患者76例,根据治疗方案分为对照组和观察组,每组38例。对照组术后采用单纯TC化疗方案治疗,观察组在对照组基础上采用参麦注射液治疗。比较2组临床疗效、免疫功能以及毒性作用发生情况。结果2组有效率、稳定率比较差异无统计学意义(P>0.05)。观察组骨髓抑制、肠道反应发生率低于对照组(P<0.05);治疗后,观察组CD3+、CD4+、CD4+/CD8+水平高于治疗前和对照组,CD8+水平低于治疗前和对照组(P<0.05,P<0.01)。结论参麦注射液联合TC化疗方案临床疗效显著,毒性作用低,可有效改善患者细胞免疫功能。
Objective To investigate the effect of Shenmai injection combined with TC chemotherapy on clinical efficacy,immune function and toxic or side effects in patients undergoing surgery for moderate and advanced ovarian cancer.Methods Seventy-six patients with moderate and advanced ovarian cancer admitted to the Second Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine from January 2017 to January 2018 were selected as subjects.According to the different treatment schemes,76 patients were divided into control group and observation group,with 38 cases in each group.The control group was treated with TC chemotherapy alone,and the observation group was treated with Shenmai injection on the basis of the control group.The clinical efficacy,immune function and toxic or side effects were compared between the two groups.Results There was no significant difference in the effective rate and stability rate between the observation group and the control group(P>0.05).The incidence of myelosuppression and intestinal reaction in the observation group was significantly lower than that in the control group(P<0.05).After treatment,the levels of CD3+,CD4+,CD4+/CD8+in the observation group were significantly lower than those before treatment and those in control group,and the CD8+level was significantly lower than that before treatment and that in control group(P<0.05,P<0.01).Conclusion Shenmai injection combined with TC chemotherapy has a significant clinical effect,low toxic or side effects,and improve the cellar immune function of patients.
作者
张媛媛
张旋
宋丽华
董玉琼
ZHANG Yuan-yuan;ZHANG Xuan;SONG Li-hua;DONG Yu-qiong(Department of Pharmacy,the Second Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine,Xianyang,Shaanxi 712000,China;Department of Gynecology,the Second Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine,Xianyang,Shaanxi 712000,China;Department of Gynecology,Ankang Traditional Chinese Medicine Hospital,Ankang,Shaanxi 725000,China)
出处
《解放军医药杂志》
CAS
2020年第7期35-37,42,共4页
Medical & Pharmaceutical Journal of Chinese People’s Liberation Army
基金
陕西省卫生和计划生育委员会项目(2016D032)。
作者简介
通讯作者:董玉琼,E-mail:juhuaidang15@163.com。
